a National Agricultural Technology Institute , Institute of Virology and Technological Innovations IVIT, CONICET-INTA, Hurlingham , Buenos Aires , Argentina.
b Human Health Therapeutics Research Center, National Research Council Canada , Montreal , Quebec , Canada.
Crit Rev Biotechnol. 2019 May;39(3):306-320. doi: 10.1080/07388551.2018.1554619. Epub 2019 Jan 17.
Foot and mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals, which causes severe economic losses in the livestock industry. Currently available vaccines are based on inactivated FMD virus (FMDV). Although inactivated virus vaccines have proved to be effective in FMD control, they have a number of disadvantages, including the need for high bio-containment production facilities and the lack of induction of immunological memory. Novel FMD vaccines based on the use of recombinant empty capsids have shown promising results. These recombinant empty capsids are attractive candidates because they avoid the use of virus in the production facilities but conserve its complete repertoire of conformational epitopes. However, many of these recombinant empty capsids require time-consuming procedures that are difficult to scale up. Achieving production of a novel and efficient FMD vaccine requires not only immunogenic antigens, but also industrially relevant processes. This review intends to summarize and compare the different strategies already published for the production of FMDV recombinant empty capsids, focusing on large-scale production.
口蹄疫（FMD）是一种偶蹄类动物的高传染性疾病，它会给畜牧业造成严重的经济损失。目前可用的疫苗是基于灭活的口蹄疫病毒（FMDV）。虽然灭活病毒疫苗已被证明对口蹄疫的防控是有效的，但它们存在一些缺点，包括需要高生物安全的生产设施，以及缺乏免疫记忆的诱导。基于使用重组空衣壳的新型口蹄疫疫苗已显示出良好的效果。这些重组空衣壳是很有吸引力的候选者，因为它们避免了在生产设施中使用病毒，但保留了其完整的构象表位谱。然而，许多这些重组空衣壳需要耗时的、难以规模化的程序。要生产出新型、高效的口蹄疫疫苗，不仅需要免疫原性抗原，还需要工业化相关的流程。这篇综述旨在总结和比较已经发表的用于生产口蹄疫病毒重组空衣壳的不同策略，重点关注大规模生产。
